Sugemalimab-related AEs occurred in > 20% of patients included proteinuria (n = 14, 48.3%), anemia (n = 13, 44.8%), blood bilirubin increased (n = 8, 27.6%), ALT increased (n = 7, 24.1%), AST increased (n = 7, 24.1%), white blood cell count decreased (n = 7, 24.1%), and bilirubin conjugated increased (n = 6, 20.7%). This evidence concerns the gene GPT and anemia.